Generating Contract Payments, Milestones and Service Revenue from the R&D Stage
First written in FY2016. 13 of 21 entries say "Restated". Latest entry: 2026-05-14.
The whole theme swung hardest in 2021: 1 of 11 companies on the "Worse" side.
7 other companies' latest entry also says "Advanced".
- 2026-05-14AdvancedEarnings
「During the consolidated fiscal year, a portion was recognized as revenue.」
Consideration relating to cell-line construction for novel biosimilars was recognized as revenue in line with development progress. - FY2026-H1AdvancedAnnual report
「Product sales 3,168,842 Income from intellectual property and other sources 107,374 Revenue from contracts with customers 3,276,217」
During the interim consolidated accounting period, the company recorded product sales of ¥3,168,842 thousand and income from intellectual property and other sources of ¥107,374 thousand, expanding its revenue base combining product sales and income from intellectual property and other sources from the same period of the previous year. - FY2025AdvancedAnnual report
「In the cell therapy business, Escator has received an upfront payment under a joint commercialization agreement with Mochida Pharmaceutical Co.,Ltd. for GCT-103, a regenerative medicine product under development for cerebral palsy.」
The revenue model generating upfront payments from the R&D stage has gained a concrete monetization result through execution of the joint commercialization agreement for GCT-103 and receipt of the upfront payment. - FY2025-H1RestatedAnnual report
「Product sales 1,643,434 Income from intellectual property and other sources 106,477 Revenue from contracts with customers 1,749,911」
The revenue model combining product sales with income from intellectual property and other sources has continued as the revenue mix for the interim consolidated accounting period. - FY2024-Q3AdvancedAnnual report
「The biosimilars business is making steady progress toward achieving the fiscal 2025 performance targets set out in the Medium-Term Management Plan—KWB2.0—announced in May 2022, alongside further future revenue growth from these four launched products.」
With the number of launched products expanding to 4, the business has progressed from a revenue base centered on product sales and income from intellectual property and other sources to a stage where further revenue growth is expected toward achieving the fiscal 2025 performance targets. - FY2024-Q2AdvancedAnnual report
「The company is now expected to make steady progress toward achieving the fiscal 2025 performance targets set out in its Medium-Term Management Plan—KWB2.0—announced in May 2022, alongside further future revenue growth from four launched products, including GBS-007, which added an indication in September 2023.」
The revenue model has progressed to the stage where the number of launched products has expanded from 3 to 4, with further revenue growth expected. - FY2023-Q3RestatedAnnual report
「Product sales 1,315,671 Income from intellectual property and other sources 214,826 Service revenue 196,363 Revenue from contracts with customers 1,726,862」
Specifically reporting the breakdown for the cumulative third quarter under a revenue model combining product sales, income from intellectual property and other sources, and service revenue. - FY2023-Q2RestatedAnnual report
「Product sales 748,201 Income from intellectual property and other sources 171,545 Service revenue 196,363 Revenue from contracts with customers 1,116,111」
Specifically reporting the breakdown for the cumulative second quarter under a revenue model combining product sales, income from intellectual property and other sources, and service revenue. - FY2023-Q1RestatedAnnual report
「Product sales 574,453 Income from intellectual property and other sources 36,425 Revenue from contracts with customers 610,878」
Reaffirming, based on this quarter's results, a revenue model that records multiple revenue sources, including income from intellectual property and other sources in addition to product sales. - FY2022RestatedAnnual report
「We have been steadily recording revenue from sales of the drug substance for filgrastim BS, a treatment for neutropenia jointly marketed in Japan by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar, which was jointly developed with Sanwa Kagaku Kenkyusho Co., Ltd. and began being marketed on 27 November 2019. In addition, the ranibizumab biosimilar jointly developed with Senzu Pharmaceutical Co., Ltd. obtained marketing approval in Japan on 27 September 2021 and was launched on 9 December 2021.」
Reaffirming an earnings model extending from the R&D stage through post-launch, with annual results including drug substance sales, royalties and post-launch revenue from the ranibizumab biosimilar. - FY2022-Q3AdvancedAnnual report
「We have been steadily recording revenue from sales of the drug substance for filgrastim BS, a treatment for neutropenia jointly marketed in Japan by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar, which was jointly developed with Sanwa Kagaku Kenkyusho Co., Ltd. and began being marketed on 27 November 2019. In addition, for the ranibizumab biosimilar jointly developed with Senzu Pharmaceutical Co., Ltd., the company obtained marketing approval in Japan from the Ministry of Health, Labour and Welfare on 27 September 2021 and began marketing it on 9 December of the same year.」
With the launch of the ranibizumab biosimilar, in addition to drug substance sales and royalty income from the darbepoetin alfa biosimilar, the revenue sources generated during R&D and after launch have expanded in concrete terms. - FY2022-Q2RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
Reaffirming a model based on drug substance sales and royalties from the darbepoetin alfa biosimilar as stable revenue sources. - FY2022-Q1RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
Reaffirming a model whose revenue sources are drug substance sales and sales-linked royalties from the darbepoetin alfa biosimilar. - FY2021-Q3RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
Reaffirming a model whose revenue sources are sales of filgrastim BS drug substance and sales-linked royalties from the darbepoetin alfa biosimilar. - FY2021-Q1RestatedAnnual report
「We are steadily recording revenue from sales of the active pharmaceutical ingredient for the neutropenia treatment Filgrastim BS by Fuji Pharma Co.,Ltd. and Mochida Pharmaceutical Co.,Ltd., as well as royalties based on sales of the darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所, which began sales on 27 November 2019.」
The company is reaffirming its model of generating revenue from active pharmaceutical ingredient sales and royalties linked to sales of the darbepoetin alfa biosimilar. - FY2020RestatedAnnual report
「The revenue model for the biosimilar business includes sales revenue from supplying pharmaceutical companies with active pharmaceutical ingredients and other main raw materials for pharmaceuticals during the R&D stage and after launch, revenue from development milestone payments based on development progress, and service revenue generated during the R&D stage by entering into joint research and development agreements and providing pharmaceutical companies with our expertise and other know-how.」
The company is reaffirming its model of generating revenue from the R&D stage by combining active pharmaceutical ingredient sales, milestones and service revenue from joint research and development. - FY2020-Q3AdvancedAnnual report
「The darbepoetin alfa biosimilar jointly developed with ㈱三和化学研究所 began sales by that company on 27 November 2019. Going forward, we will receive royalties based on sales of the product.」
Regarding the model of generating revenue from the R&D stage, the company progressed to the stage of launching sales of the darbepoetin alfa biosimilar and generating royalties linked to sales revenue. - FY2019RestatedAnnual report
「The revenue model for the biosimilar business includes sales revenue from supplying pharmaceutical companies with active pharmaceutical ingredients and other main raw materials for pharmaceuticals during the R&D stage and after launch, revenue from development milestone payments based on development progress, and service revenue generated during the R&D stage by entering into joint research and development agreements and providing pharmaceutical companies with our expertise and other know-how.」
The company is reaffirming its revenue model of combining active pharmaceutical ingredient sales, development milestones and service revenue from joint research and development. - FY2018RestatedAnnual report
「The revenue model for the biosimilar business includes sales revenue from supplying pharmaceutical companies with active pharmaceutical ingredients and other main raw materials for pharmaceuticals during the R&D stage and after launch, revenue from development milestone payments based on development progress, and service revenue generated during the R&D stage by entering into joint research and development agreements and providing pharmaceutical companies with our expertise and other know-how.」
The company is reaffirming its model of generating revenue from the R&D stage by combining active pharmaceutical ingredient sales, development milestones and service revenue from joint research and development. - FY2017RestatedAnnual report
「The revenue model for the biosimilar business includes sales revenue from supplying pharmaceutical companies with active pharmaceutical ingredients and other main raw materials for pharmaceuticals during the R&D stage and after launch, revenue from development milestone payments based on development progress, and service revenue generated during the R&D stage by entering into joint research and development agreements and providing pharmaceutical companies with our expertise and other know-how.」
The company is reaffirming its model of generating revenue from the R&D stage by combining active pharmaceutical ingredient sales, development milestones and service revenue from joint research and development. - FY2016First statedAnnual report
「By establishing a business model that generates revenue from the R&D stage, we are working to diversify the R&D risks of each development candidate.」
The model combines sales of active pharmaceutical ingredients, upfront payments, development milestones, service revenue from joint research and development, and post-launch royalties.